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Abstract 
The current study detects different morphologies related to prostate pathology using deep 
learning models; these models were evaluated on 2,121 hematoxylin and eosin (H&E) stain 
histology images captured using bright field microscopy, which spanned a variety of image 
qualities, origins (whole slide, tissue micro array, whole mount, Internet), scanning machines, 
timestamps, H&E staining protocols, and institutions. For case usage, these models were applied 
for the annotation tasks in clinician-oriented pathology reports for prostatectomy specimens. 
The true positive rate (TPR) for slides with prostate cancer was 99.7% by a false positive rate of 
0.785%. The F1-scores of Gleason patterns reported in pathology reports ranged from 0.795 to 
1.0 at the case level. TPR was 93.6% for the cribriform morphology and 72.6% for the ductal 
morphology. The correlation between the ground truth and the prediction for the relative tumor 
volume was 0.987 n. Our models cover the major components of prostate pathology and 
successfully accomplish the annotation tasks. 
Introduction 
Prostate Cancer (PCa) is the most diagnosed cancer in men and one of the most prevalent cancer-
related causes of death1. PCa is usually diagnosed via prostate needle biopsy and may result in 
patients undergoing radical prostatectomy (total removal of the prostate, seminal vesicles and 
surrounding tissues) upon histological confirmation2. Management of patients requires a reliable 
histopathological evaluation, including an initial determination of tumor extent and other cancer-
related metrics (particularly grading). However, the limited human resources and the increase in 
the workload challenge the pathologists to maintain their evaluation performance during the 
clinical routine. Moreover, the prostatectomy specimens are processed in multiple embeddings 
(up to 50) and represent one of the specimens that have the most time-consuming evaluation 
process in the anatomical pathology. 
The  results from  the histopathological evaluation are critical for decision-making and predicting 
the patient’s outcome, making reproducibility and standardization of clinical importance 3. While 
the histopathological evaluations of the prostatectomy specimens for the grading and staging of 
PCa are based on well-established guidelines4,5, standardizing the pathological evaluation has 
proven to be a challenge due to factors such as the substantial interinstitutional differences in 
laboratory techniques and human reliability  (intra-/interobserver variability)5,6. Pathologists are 
human beings whose mental capacities, visual perception, and responses are intuitively expected 
to vary at the individual level and are also influenced by socioeconomic conditions. Moreover, 
the histopathological evaluation generally represents a visual search and decoding task that 
depends on the human attentional capacity. It has been shown that human observers often differ 
in response to the same sensory stimuli for the same task, which explains the intra/interobserver 
variation in tumor grading 4,6,7. Interestingly, advance information has been shown to enhances 
the visual search performance 8. Moreover, providing prior information about the sample origin 
and location, in addition to the clinical data, has shown to improve the pathological evaluation 
9,10. Accordingly, we propose that providing prior information about the tumor extension and 
morphology can be helpful to guide a more precise histopathological evaluation. Recent 
advances in Artificial intelligence (AI) especially in computer vision has demonstrated its 
potentials for automated cancer detection and the tumor grading from histology images 11-17. 
Deep learning (DL) is a board family of the machine learning methods within the AI domain. DL is 
considered as one of the state of the art algorithms in computer vision due to its remarkable 
performance in vision detection and segmentation tasks 18. Most published works to date utilized 
publicly available “state-of-the art” neural network architectures like VGG16 19, Inception V3 20, 
ResNet 18, DenseNet 21 for tumor detection and grading problems. Several works have 
successfully shown the effectiveness of DL models in determining cancer lesions and performing 
tumor grading for PCa 11-17. However, applying such DL model architectures to the cancer 
detection and grading task is hindered by the need for expensive computational resources and 
the absence of well-annotated development datasets. An ideal DL model for the medical domain 
would be trainable on a small or mid-size data set using affordable or existing infrastructure. 
Transfer learning is an approach to train a model on small/midsize datasets by reusing the pre-
trained weights from a large dataset designed for a general image classification problem (e.g., 
ImageNet). However, the histology images are domain specific datasets that differ significantly 
from the dataset for the general image classification problems. Accordingly, optimizing the 
transfer learning remains challenging for the cancer detection problems from the histology 
images. Transfer learning further requires a complicated fine-tuning of the pretrained models 
like, for example, identifying the right layers to train the layer weights 22,23. Thus, we chose to use 
PlexusNet, a customized deep learning architecture, that provides comparable results to “state-
of-the-art” models for prostate cancer detection with limited resources23. For a real case usage, 
PlexusNet and other customized convolutional neural network architecture inspired by VGG were 
used for automated annotation to disentangle the annotation work from the pathologist’s tasks. 
For that purpose,  we utilized a framework based  on cMDX© (Clinical Map Document based on 
XML) for the generation and management of clinician-oriented pathology reports  already 
introduced by Eminaga et al  24. The cMDX framework has been applied in clinical routine to 
reporting and analyses of PCa in prostatectomy specimens 25. In this context, the topographical 
distribution of PCa foci and related pathologic findings can be evaluated using the cMDX 
documentation system 24,25. However, our previous work was limited by the dependency on the 
pathologists who delineated the tumor extension using the cMDX Editor. Additionally, the 
annotation work and the documentation of Gleason patterns and pathological morphology (i.e. 
cribriform and ductal morphology) for each lesion remained time-consuming and are thus often 
times  avoided by the pathologists. Given the restrictions of the previous works, this study will 
illustrate how AI can improve the existing framework utilized in clinical routine by taking over the 
annotation tasks and provide initial information for pathological evaluation. 
Results 
Prostate Cancer and related Findings 
The interobserver annotation agreement between CK and OK/YT was acceptable by an average 
Cohen-Kappa score of 0.8385 (range: 0.7468 - 0.9284). The detection model for prostate cancer 
was validated internally and externally on 3 datasets representing the digitalized whole-mount 
(WM) slide images, the regular whole-slide (WS) images, and TMA. The comparison analyses to 
baseline methods (e.g. Inception V3 and MobileNet V2) related to prostate cancer detection are 
already handled by Eminaga et al 23 . Although these datasets were acquired using different types 
of scanners, PCa detection achieved AUC-ROCs range between 0.954 and 0.957 or Brier score 
range between 0.046 and 0.134 per slide for WM/WS images or at spot level for TMA (Figure 1 
and Table 1). AUC-ROC reveals the classification performance at different thresholds; a higher 
AUC-ROC indicates a better classification accuracy, where a AUC-ROC of 1 represents the highest 
accuracy; the Brier score is used as a measure of the model "calibration"; the lower the brier 
score, the better the model is calibrated. A coefficient of determination (R2) of 0.987 was 
measured for the correlation between relative tumor volumes of the ground truth (the tumor 
annotation made by CK for WM images of each case was considered as ground truth) and the 
predicted relative tumor volumes in 46 cases (Supplement File 1). The paired t-test also showed 
no significant differences between the relative tumor volumes of the ground truth and the 
predicted relative tumor volumes (t-statistic: -0.499; P=0.619). The mean relative tumor volume 
was 9.95% for the ground truth and 11.0% for the predicted volume; the mean difference 
between both relative volumes was -1.08% (95% CI: -1.44 - 0.72). Our model correctly classified 
the slides in 99% (402/406) of the cases. The positive predictive value (PPV) was 99.2% and the 
negative predictive value (NPP) was 95.8%. The true positive rate (TPR) was 99.7%, while the false 
positive rate was 0.785% (Supplement File 1). 
[Removed due to copyright issue] 
Figure 1 shows the general workflow for the detection part of the current study. For simplicity, we presented the results from 
prostate cancer and for the pathology features Gleason patterns 3 and 4 and HGPIN (High-grade intraepithelial neoplasia). The 
pathology reports do not routinely include HGPIN as the clinical benefits of HGPIN are limited on final pathology reports of 
prostatectomy specimens. Detailed results are provided in supplement file 1. The tumor burden was calculated by identifying the 
average number of pixels with tumor in relation to the pixel size on the mask patches generated from the annotation data in 
each data source. w/o: without; w: with; PCA: Prostate cancer; PPV: Positive predictive value; NPV: negative predictive value; 
TPR: true positive rate, TNR: true negative rate; CA: Classification accuracy; AUC: Area under curve of the receiver operating 
characteristic curve, FMI: Fowlkes-Mallows index. * a complete ground truth (annotation) for the tumor extent of the prostate 
cancer was available for 46 cases. TCGA: The Cancer Genomics Atlas;  
 
Table 1: The slide-wise accuracies for prostate cancer detection on external datasets calculated on patch images per slide. 
 
Table 2: The accuracies for Gleason pattern detection, cribriform and ductal morphology on cases that have whole-mount sections 
of the prostate. The frequency thresholds of the finding presence required for reporting at a case level were set to 0.1% for most 
findings. 
 
 
We tested the model performance for Gleason pattern 3 (GP3) and pattern 4 (GP4) on an external 
ISUP dataset (Figure 1 and Table 3). Here, the model achieved an AUC of 0.937 and a F1-score of 
0.9 for GP3 and 0.83 for GP4. At the case level, GP3 was correctly identified in 97% of cases and 
all cases with GP4 were detected correctly. The detection model for Gleason pattern 5 (GP5) 
achieved a F1-score of 0.9 at patch level and TPR of 91.6% at case level. 
 
 
Table 3: The model accuracies for Gleason pattern detection on an external dataset from ISUP. Each image was evaluated by 
expert panel members (23 members). This dataset reached a consensus rate of 65% among pathologists. 95% Confidence 
Interval for uncertainty measurement determined by bootstrapping with 1000 replications)
 
 
The cribriform or ductal morphology was detected with AUCs of 0.928 or 0.870 at the patch level. 
At the case level, TPR for the detection of cribriform morphology was 93.6% with an overall F1-
score of 0.706 whereas TPR for the detection of ductal morphology was 72.7% with an overall 
F1-score of 0.956. 
Real Case Usage of Deep Learning Models for clinician-oriented cMDX reports 
Figure 2A/B demonstrates the annotation results and illustrates examples of the activation maps 
for different findings. By visual reviewing the cMDX reports of 55 cases for correctness of the 
annotation, we found that the tumor lesions were correctly detected and annotated for all cases. 
However, the prostate cancer detection was irritated by the histology of the ejaculatory ducts 
and falsely considered a small part of the ejaculatory ducts as tumor area in 4 cases. The accuracy 
for tumor detection is provided for each case in Supplement file 1. The finding list of each lesions 
were randomly reviewed, and we confirmed that all the finding listed for the lesion were correct. 
Figure 3 provides an overview of the user-interface for viewing the cMDX reports. An example 
cMDX file and the viewer tool are provided on GitHub 
(https://github.com/oeminaga/cmdx_report.git). The user interface provides information 
related to the presence of Prostate Cancer, Gleason patterns 3, 4 and 5, the cribriform and ductal 
morphology, and the relative/absolute tumor volume. Similar to the original cMDX report editor, 
the pathologist can provide the tumor grading according to the Gleason grading system 26, the 
tumor stage using the UICC TNM staging system 27, the extracapsular extension and the surgical 
margin status. Supplement file 2 provides an example of cMDX file that includes representative 
images of the PCa lesions. By Looking at the file sizes, 55 cMDX reports occupied 36.9 gigabytes 
whereas the corresponding gigapixel histology images required 1.4 terabytes of storage spaces. 
[Removed due to copyright issue] 
Figure 2A the slide thumbnail (Grid) was used to define a grid to split the histology image into patches, from which the tumor 
probability was determined for each patch and a heatmap was reconstructed. The generation of the heatmap was repeated for 
other findings and the heatmap for the prostate cancer was used to determine the lesion boundary (ANNO). PCA: Prostate Cancer; 
DA: Ductal morphology; CRI: Cribriform morphology; Gleason pattern 3 (GP3), 4 (GP4) or 5. Nerve and/or vessel structures 
(NERV/VES); inflammation (INF) signatures of high-grade intraepithelial neoplasia (HGPIN); Automated annotation of the lesion 
(Anno). 
[Removed due to copyright issue] 
Figure 2B the activation map for different findings. signatures of high-grade intraepithelial neoplasia (HGPIN) 
 
[Removed due to copyright issue] 
Figure 3: The graphical user interface of the cMDX report viewer (A). The user can access the original gigapixel histology images 
if these images are available on the local storage.  By clicking on the lesion (marked with red color), a second window showing 
the region appears (B). The user can zoom in or out and scroll through the lesion. The original input data were altered for 
patient’s privacy reasons. 
Discussion 
The current study demonstrated that deep learning models for different histology of prostate 
pathology are feasible. As real case usage, we demonstrated the feasibility of using these models 
for annotation tasks of the electronic cMDX (clinical map document) pathology reports as the 
original framework for the cMDX pathology reports is already part of the clinical routine in 
Prostate Center of the University Hospital Muenster for more than a decade 24,25. Our work differs 
from previous works 11,12,14,28-33 in prostate cancer and Gleason pattern detection in many 
significant ways. First, the current study covered various types of histology images including the 
whole-mount slide of a prostatectomy slice, the whole-slide image that contains a portion of the 
prostatectomy slice, a TMA slide, and internet images (i.e., ISUP images). Second, we utilized 
histology images that cover all anatomical zones of the prostate and the seminal vesicle. We 
preferred the whole-slide H&E images of prostatectomy specimens over the biopsy samples for 
this study for the following reasons. The prostate consists of four major anatomy regions (i.e., 
peripheral zone, central zone, transition zone and anterior fibromuscular stroma), where the 
peripheral zone occupies 70% of the prostate 34. Each prostatic zone has its own histological 
features that distinguish itself from other zones 34. Usually, the systematic biopsy scheme targets 
the peripheral zone as the majority of prostate cancer originates from this zone (68%). However, 
the remaining prostate cancer is located in other zones which are usually not targeted by the 
systematic biopsy scheme at the initial biopsy setting due to the low tumor probability in these 
zones 35,36.  As the maximum cylindric tissue volume for a 18-gauge biopsy side-notch needle with 
2.5 cm stroke length is 0.0316 cc 37,38 and the prostate volume ranges between 24 and 106 cc 
39,40, a single biopsy core represents a small fraction of the prostate. Thus, the prostate biopsy is 
not representative due to the heterogeneity of prostate tissue and prostate cancer and is 
associated with sampling errors 41. The pathology evaluation of prostatectomy specimens reflects 
more the real pathological conditions of the prostate cancer and provides more apparent 
pathological evidences (e.g. tumor heterogeneity, tumor volume and tumor extent) than the 
pathology evaluation of biopsy cores42. Further, the current GG system for biopsy is limited by 
many challenges associated with sampling errors, high interobserver variations, the biopsy 
targeting angles and its discrepancy to the final GG in 30-40% cases 4,43. Thus, the GG system of 
prostatectomy, if available, is preferred as reference pathology over that of prostate biopsy. For 
instance, studies evaluating the GG upgrading, a frequent situation in PCa, are considering the 
GG of the prostatectomy specimens as reference or final GG to identify cases whose final GG are 
upgraded from the biopsy GG 44,45. Another example is the Epstein criteria for active surveillance 
that was developed on the basis of the pathology evaluation of prostatectomy specimens 46,47.In 
light of this, the generalizability of the deep learning models that were developed based on 
biopsy samples or TMA for prostate cancer detection or grading remain questionable. Third, the 
current study covered different finding families and were evaluated on different datasets for 
robustness and performance consistence. The cancer detection accuracies remained stable over 
different types of histology images and scanner types. Our findings show that our model based 
on the PlexusNet architecture23 performed well in prostate cancer detection and Gleason 
patterns although it was developed by using 12.7% of the total histology images. The discrepancy 
in the performance of the HGPIN detection model between the internal validation set annotated 
by YT and the external validation set annotated by CK is due to the inconsistency in the definition 
of HGPIN lesion as the current inter-observer agreement for HPGIN is 70% according to Iczkowski 
et al 48.  Fourth, we provided a real case usage of our models by integrating the detection models 
into the electronic cMDX pathology report. The cMDX pathology report was designed from the 
urological aspect and includes information relevant for tumor classification (pT) from whole-
mounted prostatectomy specimens such as the tumor spatial distributions27 and the presence of 
Gleason patterns. Using the detection model for prostate cancer facilitated a very accurate 
estimation of the tumor volume related to the ground truth (R2:0.987). One of the challenges of 
reporting tumor volume is the accurate estimation as it is one of the reasons for controversy in 
the predictive value of tumor volume or relative tumor volume 49-53. Although no consensus 
method has emerged for measuring tumor volume, ISUP advocates for technological advances in 
imaging techniques to reinforce the clinical rationale for incorporating a size-related staging 
parameter into the pathological reporting of prostate cancers 54. Finally, we followed the clinical 
guidelines for pathological evaluation and considered the needs of urologists for 
histopathological information in the cMDX reports 24. Fifty-five cases were tested on a single GPU 
and the models were also trained on a single GPU (Titan V with 11 GB VRAM) and 2 TB PCIe flash 
memory, where one case required 35+/-6 minutes in average to complete the all finding 
detections. This duration includes the time cost for input/output access that has impacts on the 
processing speed. Thus, our models are energy efficient compared to models that require 
multiple GPUs or expensive GPU cloud solutions for training. We believe that energy-/cost-
effective AI-based solutions will receive more acceptance in healthcare as a recent survey 
showed that the majority of U.S. public (69%) advocates the need for prioritizing the reduction 
of healthcare cost by the U.S. government 55. 
Deep learning has now facilitated the automation of the time-consuming annotation procedure 
for the tumor extent and helped to shorten the considerable documentation duration required 
for the manual delineation of the tumor extent 25. Given that there is no standard validation set 
for prostate cancer to compare with results from other studies, we explicitly avoided any 
comparison with previous studies. In our opinion, performing a model comparison is artificial and 
challenging because the model optimization depends on the developers and the data 
preparation. Additionally, there is no standard configuration for hyperparameters or 
augmentations for the existing models for prostate cancer and related findings. The condition of 
the input data (e.g. the magnification level and patch size), configurations of hyperparameters 
(e.g. batch size) or augmentations (e.g. the degree of rotation) lead to different performance 
despite having the same model architecture 14,23,56,57. Moreover, there are so many deep learning 
architecture and many trimmed versions of “state-of-art” models making a reasonable model 
comparison difficult for one research team to cover the all existing deep learning models 14,28,33,58-
60. Therefore, we advocate providing detailed information related to the model architecture, the 
hardware, the hyperparameter and augmentation configuration, and conducting the model 
evaluation on a standard validation set to achieve a reasonable model comparison. To support 
the standardized performance reporting for prostate cancer detection and related finding, the 
image file list, the annotation data for TCGA images will be available for non-commercial 
research.  
The current study inherits some limitations that warrant mention. First, this study has a 
retrospective character and therefore encompasses the limitations of a retrospective study. 
Although we implemented a quality control procedure for the blurriness and brightness of 
histology images, the protective measurement may have failed to identify poor-quality images 
that may have impacted the model performance. Thus, a periodic quality control of histology 
images should be made prior to feeding the framework with histology images. There is a need to 
adapt the deployment of DL models to the existing infrastructure and resources. Further, the 
definition of the thresholds for cancer detection varies according to the application as the 
evaluation conditions for biopsy cores differs from for the evaluation conditions of 
prostatectomy specimens. Other limitations include the high expense and maintenance costs of 
the infrastructure to digitalize histology slides that continue to restrict the wide-spread usage of 
digital pathology. We believe that this issue can be resolved by having more competitors in this 
field to lower the costs to benefit small and midsize healthcare services. A potential limitation of 
this study is that many pathologists were involved in the annotation procedures. However, such 
conditions actually mimic the clinical routine and the classification performance for PCA, GP3 and 
GP4 detection were comparable between different datasets with histology images annotated by 
different pathologists. We didn’t perform any comparison to the human readers as such 
comparisons are artificial and doesn’t represent the clinical routine; The clinical routine includes 
a close communication between different clinical disciplines and physicians through many 
channels (e.g. hospital information systems, tumor boards, consulting etc..) and it is well-known 
that prior knowledge about the clinical information enhances the pathology evaluation 9,10. 
Another limitation is that the classification accuracy for Gleason pattern 5 (GP5) was moderate 
due to the low number and size of the lesions with GP5 as Gleason pattern 5 of our cases are 
tertiary Gleason patterns and the patients with GG 9-10 are often not amenable to surgical 
intervention and instead receiving hormonal deprivation and radiation therapy 61,62. However, 
the detection model for GP5 has a space for accuracy improvement and we aim to recruit more 
cases with Gleason pattern 5 to enhance the accuracy of the GP5 detection model over the time. 
Finally, we focused only on major findings related to prostate pathology and didn’t consider all 
aspects of prostate pathology. However, the purpose of the current study is to show that DL is 
feasible to determine different morphologies of prostate pathology and we do plan to expand 
the coverage to benign hyperplasia and intraductal prostate cancer based on the existing highly 
curated datasets. Our future work will focus on integrating the DL into the cMDX framework and 
conduct research evaluating the benefits of applying DL trained on prostatectomy specimens for 
biopsy pathology. 
Conclusion 
The current study introduces deep learning models for different histology of prostate pathology 
deployable for cMDX pathology report generator; it has high accuracies for cancer detection and 
the detection of related findings. 
Material and Methods 
This study used prospectively collected whole-slide diagnostic histology images (TCGA-PRAD) 
from TCGA (The Cancer Genome Atlas) and Stanford University in accordance with the privacy 
regulations and the Helsinki declaration. The study was approved by the IRB (IRB-46418). The 
histology images were stained with Hematoxylin and Eosin staining (H&E) and acquired using an 
Aperio Digital Pathology Slide Scanner -Scanner type A- from Leica Biosystem (Wetzlar, 
Germany). The TCGA images were scanned at a 40x objective zoom, whereas the Stanford images 
were scanned at a 20x objective zoom. These images were stored in SVS format.  Our cohort 
consisted of 449 H&E images from TCGA; 466 whole-mount H&E images from 65 cases who 
underwent radical prostatectomy were also considered. Additionally, we included 125 whole-
slide images representing the index lesions in 125 cases from the historic McNeal dataset that 
were scanned at 40x objective zooming level using a slide scanner from Philips (Amsterdam, 
Netherland) – Scanner B. A tissue micro array (TMA) from 339 prostatectomy specimens with 
932 spots from prostate cancer index lesions and 197 spots with normal tissues was stained with 
H&E and scanned using the Ariol microscope system manufactured by Leica -Scanner C- (Wetzlar, 
Germany). Forty-two spot images from a second TMA that have, in addition to normal tissue and 
prostate cancer, prostatic intraepithelial neoplasia was also included in our study. Finally, 220 
H&E histology images from the International Society of Urological Pathology (ISUP) reference 
library images were included (Internet, Unknown scanner vendor). In total, we collected 2,431 
H&E images that spanned a variety of image qualities, origins (WS, TMA, WM, Internet), scanning 
machines, timestamps, H&E staining protocols, and institutions. All histology images were 
capture using the bright field microscopy. For real case usage, we applied the existing cMDX 
framework for generating pathology reports for prostatectomy specimens and included the 
automated annotation of prostate cancer and related finding. A detailed description of cMDX 
framework can be obtained from Eminaga et al 24. 
Cohort for Prostate Cancer Detection 
The development set was randomly selected and consisted of 250 histology images from TCGA 
(55% of TCGA images) and 60 whole-mount histology images from 10 Stanford cases (12% of 
Stanford WM images). The main reason of including 10 cases from Stanford is the high tumor 
burden of TCGA images (Mean pixel number with tumor in percentage: 45+/-4%), which does not 
cover all aspects of histological structures of the prostate (e.g., ejaculatory duct, different forms 
of the benign hyperplasia, epithelial tissues from central zones, urethra). Therefore, we selected 
these images from Stanford that have tumor burdens below 10% of the prostate and exhibit 
different prostatic anatomic structures. The development set was then randomly split into a 
training set (80%), and a test set for internal validation (20%). The validation set for model 
training was generated by randomly selecting 10% of patch images from each case of the test 
set. 
All images were annotated for tumor lesions by experienced board-certified pathologists (CK, YT, 
MA and RW) and a urologist (OE) who all have significant experience in research related to the 
pathology of prostate cancer and its associated findings. The prostate cancer lesions of the 
whole-mount (WM) images were annotated by CK. The annotation of the tumor lesions on the 
regular whole-slide (WS) images from TCGA-PRAD and McNeal’s dataset was made by OE and 
confirmed by MA for the correctness of the annotation. The tissue micro arrays (TMA) for 
prostate cancer was already created according to the tumor status. The spots with tumors were 
obtained from lesions in prostatectomy specimens that were identified by many pathologists 
during the clinical routine. After creating the TMA, the tumor status of each TMA spot was 
evaluated and confirmed by RW. 
For external validation, we utilized three datasets with different data origins. The first validation 
set consisted of 254 whole-mount H&E images from serially sectioned prostatectomy specimens. 
The second validation set had 13 whole-slice H&E images from the McNeal dataset. The third 
external data set with H&E images came from the Stanford Tissue Microarray (TMA) Database 
with prostate cancer (n= 1,129) and was applied for evaluating detection performance. These 
histology spot images (Size: 1,024x1,024 pixels) were stained with H&E, captured at 20x objective 
magnification level. We clipped the middle region of the spot image which contains the tissue 
with relevant findings by 512x512 pixels and applied the repeated fill effect with the clipped 
image for a new image with a size of 1,024x1,024 pixels, which was then resized to 512x512 pixels 
for each H&E image. 
To evaluate the inter-observer annotation agreement, 6 whole-mount images from Stanford 
were independently annotated for the prostate cancer lesions by YT (OE refined the marked 
lesion boundaries)  and KC and the inter-observer agreement was estimated by Cohen Kappa 
after setting a grid with tiles of 512x512 pixels for each image. 
Cohort for Findings related to Prostate Cancer 
Sixty-four H&E whole slice images were randomly selected from the development set including 
58 images from Stanford and 6 images from TCGA dataset. YT annotated the regions of interests 
(ROI) covering all findings listed in Supplement file 3 and the annotation contours of ROI were 
refined by OE. Gleason grading was made in accordance with ISUP guidelines from 2016 63. The 
regions of interest were tiled by 512x512 pixels, and the resulting patch images were split after 
the stratification by case into the development sets (70%, n=44) and internal validation sets (30%, 
n=20). From the development set, we generated a training set with 90% of the development set 
and the remaining lesions were assigned to the model validation set. In order to account for class 
imbalance (arbitrary defined by a ratio of 8:1 for the majority and minority classes) when it 
occurred, we applied the oversampling of the minority class to increase the frequency of the 
patch images from the minority class. Supplement file 3 provides information regarding the 
findings that have the imbalance class problems and the applied factor to oversample the 
minority class for solving this problem. 
It is worth noting that the internal validation set (test set) consists cases that have a detailed 
morphology annotation as given in Supplement file 1 and 3. Further, we visually checked subsets 
of patch images from the internal validation set for the presence of Gleason patterns 3, 4, and 5 
to ensure that patch images represent the corresponding findings (Supplement file 1).  We didn’t 
consider the Gleason patterns less than 3 in our study as these patterns are no longer utilized in 
clinical routine due to the lack of the clinical implication4. 
Gleason grading plays an important role in clinical decision making and we wanted to ensure that 
our models for Gleason pattern 3 and 4 provide results comparable to those of experts. 
Therefore, we utilized the International Society of Urological Pathology (ISUP) reference library 
images for Gleason grading, which were graded by a majority voting of a panel of 23 expert 
members of ISUP, to externally validate our models for Gleason pattern 3 and 4 64. Here, we 
considered 220 H&E images (Size: 2048x2048 pixels, captured at 20x magnification level) having 
either 4+4 or 3+3 Gleason score for our evaluation to limit the risk of the inaccurate evaluation 
and finding uncertainty in each patch image and to increase the likelihood of the presence of a 
single finding in each patch image. Further, we wanted to ensure that our models can correctly 
detect the Gleason patterns from ISUP histology images as these images are considered as Gold 
standard and used for education purposes. We were unable to evaluate Gleason pattern 5, given 
that there are 6 images with Gleason pattern 5 concurrent with Gleason pattern 4.  High-grade 
Intraprostatic intraepithelial neoplasia (HGPIN), the most presumed precursor of prostate cancer 
65,66, is optionally reported in the pathology reports 67. So, it was important to validate the model 
for HGPIN detection by using an external validation set from a TMA containing HGPIN (20 of 42 
spots). Spots with HGPIN were labelled by a single experienced uro-pathologists (CK), whereas 
the development set with HGPIN lesions from WM images was annotated by YT and the marked 
boundaries of the lesions were refined by OE.  
Since the validation sets were acquired using scanners other than those used for the 
development set, we optimized the brightness of the patch images by multiplying with a scanner 
factor that may range between 0.01 and 1. The determination of the scanner factor is based on 
the brute force approach, which finds the best scanner factor by determining the best ROC 
performance of the model on 5 positive and 5 negative patch images from the new dataset with 
no need to re-train the model for new slide images captured by scanners other than we used for 
the development set. The screening for the best scanner factor was made at two steps by the 
sequential increasing of the scanner factor initially by 0.1 and then by 0.01 in a closed range 
containing the best factor from the initial screening. 
Generation and Labelling of Patch Images 
To define the coordinate grid for patch image generation, the smallest level of the SVS whole-
slide image was converted to grayscale. Then, the tissue region was masked by thresholding at 
the mean gray value of the gray intensity. To determine the coordinates of each patch image, the 
default patch size (512x512 pixels) was rescaled after dividing by scale factors for height and 
width. These scale factors were determined by calculating the ratio of the dimension of the 
whole-slide image at 10x to the image dimension of the highest level. Patches were generated 
with an overlap ratio of 0.2. Patches not covered by the masked tissue region were excluded in 
order to remove background images from the dataset. Finally, the grid for the patch images was 
upscaled after multiplying by the scale factors. All histological images were tiled by 512x512 
pixels (330x330 µm) at a 10x magnification level based on the grid coordinates. For labelling patch 
images used for training and validation, the ground truth was considered as a binary mask 
generated based on the annotation data that covered all findings relevant for the current study 
in each slide image. We developed a custom patch image generator that generates these masks 
for model training and evaluation by conducting a key search for required findings in the 
annotation data. Each finding was annotated on the slide images independently from other 
findings. The definition of the negative set depends on the target finding as given in Supplement 
file 1. The patch mask is extracted at the same location of the corresponding patch image. The 
percentage of positive pixels to the total image size was estimated to label each patch image 
according to the binary classification. A patch image is positive if the number of positive pixels 
meets or exceeds a threshold of 20%. By determining the threshold, the effect of potential errors 
associated with the annotation procedure was taken into account, especially in the edges of the 
annotated areas as the edge areas are more prone to annotation errors and false-positive 
conditions than other parts of the annotated region.  We also estimated the threshold by building 
an analogy to the risk of prostate cancer ranges between 15-25% by a threshold of 3-4 ng/mL for 
the serum level of prostate-specific antigen, where urologists usually consider an active 
measurement by the given risk for prostate cancer 68. 
Color Intensity Optimization for Hematoxylin Eosin for aged whole-slide H&E images 
A long storage period of H&E slides from McNeal datasets > 10 years and aging processes caused 
paled H&E staining of these slides. Specially, the nuclei staining is affected the most by aging. In 
order to reconstruct the color intensity, we developed an algorithm specific for the color intensity 
correction of H&E McNeal images inspired by Macenko’s approach 69. Before feeding the patch 
images for any prediction procedures, we converted the RGB color space of the patch images 
into the optical density (OD) space for red, green and blue channels. Then, we restricted the OD 
ranges between 0.5 and 0.95 and excluded extreme values of OD. After that, we calculated the 
covariance matrix of a single patch image first by combining the color channels with itself and 
then with each other and calculated the mean covariance matrix from all channel combinations. 
Finally, the eigen vector was calculated using the mean covariance matrix and equalized to the 
stain vector.  The determination of the stain vector occurs once for each WS H&E image using 
the first patch image. 
The obtained stain vector is applied to optimize the color intensity of nuclei for all patch images 
originated from McNeal’s whole-slide H&E images by multiplying the stain vector with the OD for 
each patch image. Finally, the OD matrices for red and green and blue channels were converted 
back to the matrices with the RGB color space. The patch image is corrected by merging the 
converted matrices and the original RGB patch image. An example showing a patch image before 
and after applying the H&E color optimization is provided in Supplement file 1. 
 
Deep Learning models for Cancer Detection and Detection of other findings relevant for 
pathology report 
Supplement file 3 provides information related to the cohort constitution, the model 
architecture, and the hyperparameters applied for each finding considered in our screening 
report. Additional information about the CNN architecture of each model can also be obtained 
from supplement file 1. Most models were trained using the optimization algorithm Adaptive 
Moment Estimation (i.e., ADAM) instead of Stochastic Gradient Descent 70. The gradient Noise 
was applied for models to improve the model learning as the noise induced by the stochastic 
process aids generalization by reducing overfitting 71. The maximum number of training epochs 
was set to either to 50 or 20 and an early stopping algorithm was used to stop training after five 
consecutive epochs with not improvement in the classification accuracy. The batch size was 
defined as 16. Relevant findings other than cancer were delineated on the randomly selected 62 
H&E images from Stanford and TCGA by OE under supervision of MA and YT. The relevant findings 
and their proportions in the development and test sets for each model are listed in Supplement 
file 1 and 3. After that, the regions of interests were extracted and tiled by 512x512 pixels and 
applying an overlap rate of 0.5. These tiled images were split into a training set, validation set, 
and test set. CLAHE (Contrast Limited Adaptive histogram equalization) was applied for some 
models in order to optimize the image contrast and all pixel values were normalized by 1/255. 
We applied class weighting, oversampling, and image augmentation of rare findings to reduce 
the class imbalance effect and increase the presence probability of these scarce findings in the 
batch sequence during the model training. 
The image augmentation included rotation, horizontal and vertical flips, image shearing, and 
zooming and brightness manipulation. Additionally, we applied random RGB channel shifting and 
random modification of the image quality by changing the JPEG compression rate for certain 
findings. 
Planimetric Cancer volume estimation 
The prostate volume was calculated after formalin fixation by weighing the prostate specimen 
without the seminal vesicles. For the purpose of our study, the prostate weight in grams was 
considered roughly equivalent to its volume in cubic centimeters (cm3); the tumor/entire gland 
ratio is then used to calculate the volume of the tumor in cm3. A correction factor for tissue 
shrinkage after formalin fixation was not considered. The computational tumor volume estimate 
was performed on the basis of the volumetric calculation. Every tumor focus in each slice is 
estimated by counting the pixels affected by PCa. The cancer area is then divided by the slice area 
occupied by the prostatic slice and then added to calculate the relative cancer volume. Finally, 
the total relative cancer volume is multiplied with the prostate volume to calculate the cancer 
volume in cm3. 
Study Cohort for the accuracy evaluation of pathology screening reports 
Slides of sequential whole-mount slices from 55 cases that underwent prostatectomy were 
scanned at a 20x objective zoom and then fed into the cMDX framework. The whole-mount H&E 
histology slides were digitalized for all slices of the prostate from prostatectomy specimens in 
each case. The Gleason patterns were extracted from pathology reports of these cases using a 
natural language process and the keyword search. These extracted findings were further checked 
for correctness by manually reviewing the pathology reports and then compared with the 
reported Gleason pattern in the automated pathology reports. The pathology reports and H&E 
slide images were evaluated for the presence of ductal and cribriform morphology at the case 
level ( OE evaluated the pathology reports and shared anonymized histology images with MA for 
evaluation). The relative tumor volume was compared between the ground truth annotation 
made by CK and the relative tumor volume calculated by the cMDX pathology report. 
Evaluation metrics 
The classification performance of the final test set for pathological findings was evaluated once 
using classification accuracy, precision, recall, F-measure (F1 score), Area Under of the Receiver 
Operating Characteristics curve (AUC-ROC), and Brier score. F1-score is the harmonic mean 
between of the precision and recall applied for the measurement of the classification 
performance and imbalanced classification problems. The Fowlkes-Mallows index (FMI) is 
defined as the geometric mean between of the precision and recall and generally used for the 
similarity measurement between two groups. The Brier score measures the accuracy of 
probabilistic predictions for binary outcome and can also be used as “calibration” measurement 
of the prediction model. We evaluated the classification performance slide-wise, spot-wise, and 
patch-wise for prostate cancer, and case-wise, patch-wise or spot-wise for Gleason patterns 3 
and 4. The presence of Gleason pattern 5 was evaluated at the case level.  The classification 
performance of the framework for ductal and cribriform morphology was evaluated at the case 
level as well. Given that vessel and nerves are widely spread inside the prostate, we considered 
only the internal validation. The coefficient of the regression score determined the correlation of 
relative tumor volumes between the ground truth and the cMDX framework at case level. The 
pair-wise student t-test was applied to identify the significance of variation between the ground 
truth and the cMDX/PlexusNet-based tumor extent detection for relative tumor volume. The 
reported p-value is two-sided and statistical significance was assumed as P ≤ 0.05.  
 Our analyses were based on Python 3.6 (Python Software Foundation, Wilmington, DE) or R 3.5.1 
(R Foundation for Statistical Computing, Vienna, Austria) and applied the Keras library which is 
built-on the TensorFlow framework, to develop the models. All analyses were performed on a 
GPU machine with 32-core AMD processor with 128 GB RAM (Advanced Micro Devices, Santa 
Clara, CA), 2 TB PCIe flash memory, 5 TB SDD Hard disks, and a single NVIDIA Titan V GPU with 12 
GB VRAM. 
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